ES2179352T3 - Compuesto de pirazolopiridina y su uso farmaceutico. - Google Patents

Compuesto de pirazolopiridina y su uso farmaceutico.

Info

Publication number
ES2179352T3
ES2179352T3 ES97930832T ES97930832T ES2179352T3 ES 2179352 T3 ES2179352 T3 ES 2179352T3 ES 97930832 T ES97930832 T ES 97930832T ES 97930832 T ES97930832 T ES 97930832T ES 2179352 T3 ES2179352 T3 ES 2179352T3
Authority
ES
Spain
Prior art keywords
pirazolopiridine
formula
group
rent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97930832T
Other languages
English (en)
Inventor
Atsushi Akahane
Satoru Kuroda
Hiromichi Itani
Yasuyo Shimizu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2179352T3 publication Critical patent/ES2179352T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE PRESENTA UNA COMPUESTO DE PIRAZOLOPIRIDINA DE LA FORMULA (I) EN DONDE R 1 ES ARILO , Y R 2 ES ALQUILO INFE RIOR SUSTITUIDO CON UN GRUPO HETEROMONOCICLICO INSATURADO DE ENTRE 3 Y 8 MIEMBROS QUE CONTIENE 1 O 2 ATOMOS DE AZUFRE Y DE 1 A 3 ATOMOS DE NITROGENO QUE PUEDE TENER UNO O MAS SUSTITUYENTES; UN GRUPO DE LA FORMULA (I) EN DONDE R 3 ES HIDROGENO, ALQUILO INFERIOR, ARALQUILO INFERIOR O ACILO, R 4 ES HIDROGENO O HIDROXIDO, A ES ALQUILENO INFERIOR, M ES UN ENTERO ENTRE 0 Y 1, Y N ES UN ENTERO ENTRE 1 Y 2; UN GRUPO DE LA FORMULA (II) EN DONDE R 5 Y R 6 SON CADA UNA ALQUILO INFERIOR; O QUINUCLIDINILO, O UNA SAL DEL MISMO. EL COMPUESTO DE PIRAZOLOPIRIDINA (I) Y SU SAL DE LA INVENCION SON ANTAGONISTAS DE LA ADENOSINA Y SON UTILES PARA LA PREVENCION Y/O EL TRATAMIENTO DE LA DEPRESION, LA DEMENCIA (POR EJ. LA ENFERMEDAD DE ALZHEIMER, LA DEMENCIA CEREBROVASCULAR, LA ENFERMEDAD DE PARKINSON), LA ANSIEDAD, EL DOLOR, LA ENFERMEDAD CEREBROVASCULAR (POR EJ. ATAQUES, ETC), INSUFICIENCIA CARDIACA Y SIMILARES.
ES97930832T 1996-07-18 1997-07-17 Compuesto de pirazolopiridina y su uso farmaceutico. Expired - Lifetime ES2179352T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO1110A AUPO111096A0 (en) 1996-07-18 1996-07-18 New compound

Publications (1)

Publication Number Publication Date
ES2179352T3 true ES2179352T3 (es) 2003-01-16

Family

ID=3795426

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97930832T Expired - Lifetime ES2179352T3 (es) 1996-07-18 1997-07-17 Compuesto de pirazolopiridina y su uso farmaceutico.

Country Status (13)

Country Link
US (1) US6124456A (es)
EP (1) EP0925299B1 (es)
JP (1) JP2000514821A (es)
KR (1) KR20000067875A (es)
CN (1) CN1230186A (es)
AT (1) ATE224893T1 (es)
AU (1) AUPO111096A0 (es)
CA (1) CA2260990A1 (es)
DE (1) DE69715891T2 (es)
EA (1) EA001899B1 (es)
ES (1) ES2179352T3 (es)
HU (1) HUP9903527A2 (es)
WO (1) WO1998003507A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999067239A1 (en) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds and medicinal uses thereof
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AU4431000A (en) * 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
AU5260601A (en) * 2000-04-26 2001-11-07 Eisai Co Ltd Medicinal compositions promoting bowel movement
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
EP1601649A4 (en) 2003-02-19 2009-03-04 Endacea Inc A1-adenosine receptor antagonistic
AU2003901647A0 (en) * 2003-04-04 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Novel Condensed Furan Compounds and Pharmaceutical Use Thereof
US7247639B2 (en) 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CN103381166A (zh) * 2013-07-04 2013-11-06 丁圣雨 Chukrasone A在治疗或预防急性心衰的药物中的应用
GB201612938D0 (en) 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
GB201801562D0 (en) 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
CN113365696A (zh) * 2018-12-06 2021-09-07 阿尔麦克探索有限公司 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途
MX2021006542A (es) * 2018-12-06 2021-07-07 Almac Discovery Ltd Inhibidores de la usp19 para usarse en terapia.
WO2022083741A1 (zh) * 2020-10-23 2022-04-28 上海辉启生物医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途
AU2023293118A1 (en) * 2022-06-15 2025-01-02 Genetic Intelligence, Inc Pyridazinone-derived compounds for the modulation of myc and for medical uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5179103A (en) * 1987-06-15 1993-01-12 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
DE69315836T2 (de) * 1992-06-10 1998-04-09 Fujisawa Pharmaceutical Co Pyrazolpyridine für die behandlung der anämie
CN1046724C (zh) * 1993-12-29 1999-11-24 藤泽药品工业株式会社 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途

Also Published As

Publication number Publication date
EP0925299B1 (en) 2002-09-25
ATE224893T1 (de) 2002-10-15
AUPO111096A0 (en) 1996-08-08
CA2260990A1 (en) 1998-01-29
EA001899B1 (ru) 2001-10-22
EA199900135A1 (ru) 1999-06-24
JP2000514821A (ja) 2000-11-07
HUP9903527A2 (hu) 2000-03-28
DE69715891T2 (de) 2003-06-05
WO1998003507A1 (en) 1998-01-29
DE69715891D1 (de) 2002-10-31
CN1230186A (zh) 1999-09-29
KR20000067875A (ko) 2000-11-25
US6124456A (en) 2000-09-26
EP0925299A1 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
ES2179352T3 (es) Compuesto de pirazolopiridina y su uso farmaceutico.
ES2138977T3 (es) Agonistas muscarinicos.
MX9703186A (es) Antagonistas del receptor del neuropeptido y de indolilo.
SV1996000033A (es) Isotiazolonas
DK0729468T3 (da) Ikke-peptid tachykinin-receptor-antagonister
ES2195970T3 (es) L-ribavirina y usos de la misma.
MX9101869A (es) Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
SV1998000029A (es) Compuestos de pirazina ref. pg3186
ES2089846T3 (es) Microorganismos para la produccion de triptofano y procedimiento para su produccion.
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
MX9305294A (es) Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende.
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
ES2164088T3 (es) Antagonistas de la sustancia p para el tratamiento de la emesis.
DE59000024D1 (de) Verwendung von rheniumorganischen verbindungen zur oxidation von c-c-mehrfachbindungen, darauf basierende oxidationsverfahren und neue rheniumorganische verbindungen.
ES2052629T3 (es) Pirazolo(3,4-d)piridinas, procedimiento para su preparacion y utilizacion como medicamentos.
AR027113A1 (es) Piperidinas sustiutidas, medicamentos que contienen estos compuestos y procedimiento par su preparacion
ES2164684T3 (es) Uso de antagonistas de taquiquininas en el tratamiento de emesis.
NO943133D0 (no) Benzodiazepinderivater egnet til bruk som CCK-reseptorantagonister
ES2071663T3 (es) Analogo de fluoxetina.
AR026470A1 (es) Un compuesto de pirazolpirazina, proceso para prepararlo, las composiciones farmaceuticas que lo contienen y su preparacion, y el uso de dichos compuestospara la preparacion de medicamentos.
MX16046A (es) Procedimiento para la preparacion de 2-amino-1,2,3,4-tetrahidronaftalenos substituidos en el anillo,compuesto obtenido y composicion farmaceutica que lo incluye
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina
ES2057341T3 (es) Ciclohexenos substituidos como agentes para el sistema nervioso central.
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.